Cytocom, Inc.
CBLI · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.53 | 1.19 | 2.37 | -0.10 |
| FCF Yield | -1.02% | -0.49% | -1.76% | -2.67% |
| EV / EBITDA | -105.93 | -112.52 | -62.01 | -30.95 |
| Quality | ||||
| ROIC | -4.96% | -3.92% | -20.79% | -28.81% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.30 | 0.67 | 1.13 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -64.72% | -54.14% | -38.64% | -29.10% |
| Free Cash Flow Growth | -136.98% | 53.94% | -15.48% | -43.29% |
| Safety | ||||
| Net Debt / EBITDA | 20.59 | 26.78 | 2.81 | 3.68 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -272.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 3,940,336,652,189.46 | 278.81 |